Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 19, 2009

View Archived Issues

Novel cytochrome P450 inhibitors in early development at Gilead

Bial Portela discloses FAAH inhibitors for the treatment of pain and other conditions

Vertex presents new JAK2 inhibitors for treatment of myeloproliferative disorders

Alios BioPharma describes RNAseL inhibitors in early development

Novel checkpoint kinase inhibitors claimed by DCB-USA

Schering-Plough claims GR agonists for the treatment of allergic and inflammatory conditions

Ligand patent covers novel SARMs for treatment of musculoskeletal and other disorders

Amgen reports results for second quarter 2009

BioSante reports LibiGel safety data from phase III program

Meda launches Edluar in the U.S.

GlaxoSmithKline and Genmab report results from Arzerra study in NHL

Immunomedics obtains FDA approval to initiate phase I/II myeloma study

Crucell receives NIH award for development of influenza monoclonal antibodies

GlycoMimetics receives grant to study E-selectin small molecule antagonists

Vectibix improved progression-free survival in phase III colorectal cancer trial

Mount Sinai added as site for phase II PH-10 trial for psoriasis

Neuropeptide S receptor antagonists developed at Merck & Co.

Phase I data describe MP-470 plus chemotherapy in SCLC and neuroendocrine tumors

OSI Pharmaceuticals describes discovery of oncolytic agent OSI-906

Thrombin inhibitors FM-19 and TH-146 have anticancer activity

GSK works toward oral calcium-sensing receptor antagonists for osteoporosis

Almirall develops antedrug PDE4 inhibitors for psoriasis

Lilly reports results from phase III GJAD GENERATIONS trial of arzoxifene

FDA accepts for review BioAlliance's NDA for Lauriad for OPC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...